Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Kidney disease manifests clinically as elevated albumin excretion rate (AER), impaired glomerular filtration rate (GFR), or both, and is a cause of substantial morbidity and mortality in type 1 diabetes (T1D). The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study tested whether intensive diabetes therapy (INT) aimed at lowering glucose concentrations as close as safely possible to the normal range reduces the risks of kidney disease and other diabetes complications. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants with T1D were randomly assigned to INT or conventional diabetes therapy (CON) for a mean duration of 6.5 years. Subsequently, participants have been followed for 18 years in the ongoing observational EDIC. Standardized longitudinal measurements of AER, estimated GFR, and blood pressure were made throughout the DCCT/EDIC. RESULTS: During the DCCT, INT reduced the risks of incident microalbuminuria (AER ≥40 mg/24 h) and macroalbuminuria (AER ≥300 mg/24 h) by 39% (95% CI 21–52%) and 54% (29–74%), respectively. During EDIC years 1–8, participants previously assigned to DCCT INT continued to experience lower rates of incident microalbuminuria and macroalbuminuria, with risk reductions of 59% (39–73%) and 84% (67–92%), respectively. Beneficial effects of INT on the development of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) and hypertension became evident during combined DCCT/EDIC follow-up, with risk reductions of 50% (18–69%) and 20% (6–21%), respectively, compared with CON. CONCLUSIONS: In the DCCT/EDIC, INT resulted in clinically important, durable reductions in the risks of microalbuminuria, macroalbuminuria, impaired GFR, and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this section, the focus is on CKD attributed to diabetes in adults, which occurs in 20-40% of people with diabetes (1-4).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while the glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m 2 , the kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/ 1.73 m 2 even with no significant change in glucose (4,29,31,107,123,127,129,130).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Hyperglycemia is a known risk factor for the development and progression of both DPN and CKD.9–12”
From Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 1×
“A large body of evidence demonstrates that hyperglycemia contributes to the damage of target organs, including the kidney (5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102 · cited 1×
“The Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate GFR from calibrated serum creatinine, age, sex, and race (13).”
MethodNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 2×
“The DCCT enrolled 1,441 people with T1D from 1983–1989 to determine the effects of INT on the long-term complications of diabetes (7,9).”
BackgroundMethod(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067 · cited 1×
“In early cohort studies, up to 40% of patients with T1D developed macroalbuminuria (AER $300 mg/24 h), and up to 75% of these patients progressed to end-stage renal disease (ESRD) within 10 years (1,2).”
BackgroundIntensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Cited by
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
Diabetic kidney disease: world wide difference of prevalence and risk factors.
Gheith, O. A. A., Othman, N. F., Nampoory, N., Halim, M. A., & Al-Otaibi, T. (2016) · PubMed Central · Cited by 708
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 377
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Diabetic nephropathy—emerging epigenetic mechanisms
Kato, M., & Natarajan, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.116 · Cited by 318
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy
Sifuentes-Franco, S., Padilla-Tejeda, D. E., Carrillo-Ibarra, S., & Miranda-Díaz, A. G. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1875870 · Cited by 300
“In a subanalysis, it was discovered that the management with 10mg and 80mg of atorvastatin increases the glomerular filtration rate [87], while in the test of preventive intervention in kidney disease and ESRD (PREVEND-IT), the treatment with 40mg of pravastatin did not improve the GFR [88].”
Influential11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.024 · Cited by 278
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
Diabetic Nephropathy: a Tangled Web to Unweave
Magee, C., Grieve, D. J., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 190
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 170
Ocular Complications of Diabetes and Therapeutic Approaches
Vieira-Potter, V. J., Karamichos, D., & Lee, D. J. (2016) · BioMed Research International · doi:10.1155/2016/3801570 · Cited by 167
“For example, studies have shown that poor glucose control in the early stages of diabetes, even if corrected, still may have lasting effects on prognosis of complications long-term [176].”
BackgroundMayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000991 · Cited by 162
Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
Lytvyn, Y., Perkins, B. A., & Cherney, D. Z. I. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.10.013 · Cited by 152
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi-Klug, R. A., Braffett, B. H., White, N. H., Sherwin, R. S., Service, F. J., Lachin, J. M., Tamborlane, W. V., & the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2017) · Diabetes Care · doi:10.2337/dc16-2723 · Cited by 137
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
“However, surrogate endpoints including albuminuria, and new-onset CKD or hypertension were attenuated by intensified glycemic control and sustained for more than 20 years after the end of the randomized phase of the study.(26)”
BackgroundGubitosi-Klug, R. A., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2148 · Cited by 130
Risk Factors for Kidney Disease in Type 1 Diabetes
Perkins, B. A., Bebu, I., de Boer, I. H., Molitch, M., Tamborlane, W., Lorenzi, G., Herman, W., White, N. H., Pop-Busui, R., Paterson, A. D., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2062 · Cited by 128
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
Kogot-Levin, A., Hinden, L., Riahi, Y., Israeli, T., Tirosh, B., Cerasi, E., Mizrachi, E. B., Tam, J., Mosenzon, O., & Leibowitz, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107954 · Cited by 126
Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study
de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02870316 · Cited by 114
Bjornstad, P., Cherney, D. Z., Snell-Bergeon, J. K., Pyle, L., Rewers, M., Johnson, R. J., & Maahs, D. M. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv121 · Cited by 111
Obreli-Neto, P. R., Marušić, S., Guidoni, C. M., Baldoni, A. O., Renovato, R. D., Pilger, D. A., Cuman, R. K. N., & Pereira, L. R. L. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.1.66 · Cited by 113
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Diabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 117
“Furthermore, extended observational data from the EDIC (Epidemiology of Diabetes Interventions and Complications) study on the original DCCT cohort clearly exhibited durability of early intensive diabetic regulation beyond 18 years [6, 30, 31].”
BackgroundWinocour, P. H. (2018) · Diabetic Medicine · doi:10.1111/dme.13564 · Cited by 115
Ameliorating Chronic Kidney Disease Using a Whole Food Plant-Based Diet
Adair, K. E., & Bowden, R. G. (2020) · Nutrients · doi:10.3390/nu12041007 · Cited by 93
Wang, Y., Zhao, J., Qin, Y., Yu, Z., Zhang, Y., Ning, X., & Sun, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908219 · Cited by 110
“About 20%-40% of diabetics can develop diabetic kidney disease (DKD) (2, 3).”
BackgroundMethodDeng, N., Zhang, X., Zhao, F., Wang, Y., & He, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12742 · Cited by 88
Gembillo, G., Ingrasciotta, Y., Crisafulli, S., Luxi, N., Siligato, R., Santoro, D., & Trifirò, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094824 · Cited by 113
“DKD is more frequent in AfricanAmericans, Asian-Americans, and Native Americans than in non-Hispanic whites with T2DM [22].”
BackgroundKoška, J., Gerstein, H. C., Beisswenger, P. J., & Reaven, P. D. (2022) · Diabetes Care · doi:10.2337/dc21-2196 · Cited by 89
Lin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Peytam, F., Takalloobanafshi, G., Saadattalab, T., Norouzbahari, M., Emamgholipour, Z., Moghimi, S., Firoozpour, L., Bijanzadeh, H. R., Faramarzi, M. A., Mojtabavi, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91473-z · Cited by 74
The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
Steenbeke, M., Speeckaert, R., Desmedt, S., Glorieux, G., Delanghe, J., & Speeckaert, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073439 · Cited by 82
Diabetic kidney disease: difference in the prevalence and risk factors worldwide
Gheith, O. A. A., Othman, N. F., Nampoory, N., Halimb, M., & Al-Otaibi, T. (2016) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/1110-9165.197379 · Cited by 90
Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease
Kuo, I.-C., Lin, H. Y.-H., Niu, S.-W., Hwang, D.-Y., Lee, J.-J., Tsai, J.-C., Hung, C.-C., Hwang, S.-J., & Chen, H.-C. (2016) · Scientific Reports · doi:10.1038/srep20028 · Cited by 70
Vaisar, T., Kanter, J. E., Wimberger, J., Irwin, A. D., Gauthier, J., Wolfson, E. A., Bahnam, V., Wu, I., Shah, H., Keenan, H. A., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0772 · Cited by 73
Anderson, S. M., Buckingham, B. A., Breton, M. D., Robic, J. L., Barnett, C. L., Wakeman, C. A., Oliveri, M. C., Brown, S. A., Ly, T. T., Clinton, P. K., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0018 · Cited by 68
Lu, X., & Zhao, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_7 · Cited by 91
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110908 · Cited by 63
Measured GFR in Routine Clinical Practice—The Promise of Dried Blood Spots
Bjornstad, P., Karger, A. B., & Maahs, D. M. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.09.003 · Cited by 72
“In addition, longitudinal changes in eGFR may not reflect changes in measured GFR (mGFR) (5, 6).”
BackgroundBebu, I., Braffett, B. H., Orchard, T. J., Lorenzi, G. M., Lachin, J. M., & the DCCT/EDIC Research Group (2019) · Diabetes Care · doi:10.2337/dc18-1613 · Cited by 62
Recent advances in managing and understanding diabetic nephropathy
Tang, S. C. W., Chan, G. C. W., & Lai, K. N. (2016) · F1000Research · doi:10.12688/f1000research.7693.1 · Cited by 63
Peytam, F., Adib, M., Shourgeshty, R., Firoozpour, L., Rahmanian-Jazi, M., Jahani, M., Moghimi, S., Divsalar, K., Faramarzi, M. A., Mojtabavi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59079-z · Cited by 59
Maftei, O., Pena, A. S., Sullivan, T., Jones, T. W., Donaghue, K. C., Cameron, F. J., Davis, E., Cotterill, A., Craig, M. E., Gent, R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0700 · Cited by 53
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes
Lizotte, F., Denhez, B., Guay, A., Gévry, N. Y., Côté, A. M., & Geraldes, P. (2016) · Diabetes · doi:10.2337/db16-0254 · Cited by 58
Yao, X., Zhang, J., Zhang, X., Jiang, T., Zhang, Y. S., Dai, F., Hu, H., & Zhang, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1131395 · Cited by 73
Ding, Q., Gao, Z., Chen, K., Zhang, Q., Hu, S., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883410 · Cited by 55
Update on Estimation of Kidney Function in Diabetic Kidney Disease
Bjornstad, P., Cherney, D. Z. I., & Maahs, D. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0633-2 · Cited by 52
An, X., Liao, G., Chen, Y., Luo, A., Liu, J., Yuan, Y., Li, L., Yang, L., Wang, H., Liu, F., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1401-z · Cited by 50
Evans, M., Morgan, A. R., Patel, D., Dhatariya, K., Greenwood, S. A., Newland‐Jones, P., Hicks, D., Yousef, Z. R., Moore, J., Kelly, B., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00963-2 · Cited by 57
“There is marked difference with regards to ethnicity in the epidemiology of CKD in people with and without T2D, with Native Americans, Hispanics and African-Americans having a greater risk of developing end stage kidney disease (ESKD) compared with non-Hispanic Whites [100, 109].”
BackgroundFu, J., Shinjo, T., Li, Q., St-Louis, R., Park, K., Yu, M. G., Yokomizo, H., Simão, F., Huang, Q., Wu, I., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155260 · Cited by 53
Mitochondrial Activity and Skeletal Muscle Insulin Resistance in Kidney Disease
Carré, J. E., & Affourtit, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112751 · Cited by 52
Novel therapeutic approaches for diabetic nephropathy and retinopathy
Usuelli, V., & Rocca, E. L. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.003 · Cited by 49
Glycemic Control as Primary Prevention for Diabetic Kidney Disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.003 · Cited by 47
Liu, J., Gao, L., Fu, B., Yang, H., Zhang, L., Che, S.-Q., Xu, Y., Du, X., Liu, Z., Xue, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154079 · Cited by 49
Diabetic nephropathy: What does the future hold?
Montero, R., Covic, A. C., Gnudi, L., & Goldsmith, D. J. A. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1121-y · Cited by 45
Present and Future in the Treatment of Diabetic Kidney Disease
Quiroga, B., Arroyo, D., & de Arriba, G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/801348 · Cited by 40
“This effect has been proved valid in both type 1 and type 2 DKD and in the short and long terms [10–16].”
BackgroundQSAR studies in the discovery of novel type-II diabetic therapies
Abuhammad, A., & Taha, M. O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1118046 · Cited by 40
Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies
Bjornstad, P., Cherney, D. Z. I., Maahs, D. M., & Nadeau, K. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0708-0 · Cited by 41
Shao, B., Zelnick, L. R., Wimberger, J., Himmelfarb, J., Brunzell, J. D., Davidson, W. S., Snell‐Bergeon, J. K., Bornfeldt, K., de Boer, I. H., & Heinecke, J. W. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312556 · Cited by 35
Malek, V., Sharma, N., Sankrityayan, H., & Gaikwad, A. B. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.027 · Cited by 36
Nabrdalik, K., Kwiendacz, H., Moos, J., Moos, Ł., Kulpa, J., Brzoza, Z., Stompór, T. P., Gumprecht, J., & Lip, G. Y. H. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101726 · Cited by 48
Bilir, S. P., Hellmund, R., Wehler, B., Li, H., Munakata, J., & Lamotte, M. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.2.73 · Cited by 34
Epigenetic Alterations in Podocytes in Diabetic Nephropathy
Sugita, E., Hayashi, K., Hishikawa, A., & Itoh, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759299 · Cited by 38
“…control at the early stage of Type 1 diabetes delayed the progression of microvascular complications, including nephropathy and neuropathy, compared to conventional therapy, despite similar mean hemoglobin A1c (HbA1c) control at the later stage (de Boer, 2014; Nathan, 2014; Chen et al., 2016).”
BackgroundRecent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 36
“glucose concentrations, and in addition to chronic hyperglycemia, even transient increases in blood glucose may have long-term influence on the progression of DKD [27,28].”
BackgroundClinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14769 · Cited by 42
Cefalu, W. T., & Ratner, R. E. (2013) · Diabetes Care · doi:10.2337/dc13-2369 · Cited by 31
Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes
Reid, L. J., Baxter, F., & Forbes, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14570 · Cited by 34
Williams, M. E., Mittman, N., Ma, L., Brennan, J. I., Mooney, A., Johnson, C. D., Jani, C. M., Maddux, F. W., & Lacson, E. (2015) · Hemodialysis International · doi:10.1111/hdi.12312 · Cited by 30
Xu, M., Bi, Y., Huang, Y. F., Xie, L., Hao, M., Zhao, Z., Xu, Y., Lu, J., Chen, Y., Sun, Y., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.032 · Cited by 29
“…renal outcomes, including lowering risk of albuminuria and increasing estimated GFR (eGFR) (de Boer C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). et al., 2011; DCCT/EDIC research group, 2014; de Boer, 2014), suggesting a possible causal link between diabetes and renal outcomes.”
BackgroundInfluentialRenoprotection: focus on TRPV 1, TRPV 4, TRPC 6 and TRPM 2
Markó, L., Mannaa, M., Haschler, T. N., Krämer, S., & Gollasch, M. (2016) · Acta Physiologica · doi:10.1111/apha.12828 · Cited by 31
Mesangial Cells in Diabetic Kidney Disease: From Mechanisms to Therapeutic Implications
Li, F., Feng, Y., Ren, Q., Fu, P., & Ma, L. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.114907 · Cited by 36
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
“Intensive therapy resulted in a reduced risk of albuminuria and eGFR decline, extending beyond the randomisation period, indicating the importance of early glycaemic control in preventing long-term adverse kidney outcomes [18].”
BackgroundAspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A
Carranza, K., Verón, D., Cercado, A. G., Bautista, N., Pozo, W., Tufró, A., & Verón, D. (2015) · Nefrología · doi:10.1016/j.nefro.2015.05.013 · Cited by 36
Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes
Rubin, M. R., de Boer, I. H., Backlund, J. C., Arends, V. L., Gubitosi‐Klug, R., Wallia, A., Gregory, N. S., Barnie, A., Burghardt, A. J., Lachin, J. M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac099 · Cited by 26
Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition
Tanemoto, F., Nangaku, M., & Mimura, I. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1003227 · Cited by 29
“…al., 2021); a series of largescale clinical studies show that former episodes of hyperglycemia pose a continuing risk of diabetic complications, even if the blood glucose level is subsequently maintained within normal limits (Holman et al., 2008; de Boer et al., 2011; de Boer, 2014; Nathan, 2014).”
BackgroundPathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing
Hinden, L., Kogot‐Levin, A., Tam, J., & Leibowitz, G. (2021) · FEBS Journal · doi:10.1111/febs.15790 · Cited by 30
Metabolic memory: mechanisms and implications for diabetic vasculopathies
Zhang, E., & Wu, Y. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4710-6 · Cited by 27
Shikata, K., Haneda, M., Ninomiya, T., Koya, D., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., Uzu, T., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13339 · Cited by 24
Yu, G., Zhang, M., Gao, L., Zhou, Y., Qiao, L., Yin, J., Wang, Y., Zhou, J., & Ye, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.004 · Cited by 25
Stadler, M., Peric, S., Strohner-Kaestenbauer, H., Kramar, R., Kaestenbauer, T., Reitner, A., Auinger, M., Kronenberg, F., Irsigler, K., Amiel, S. A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2701 · Cited by 24
“The almost three decade follow up of the DCCT cohorts in EDIC cohort shows that the intervention (intensively-treated) group had a strikingly better cardiovascular (18, 19) and renal (20) outcome than the control (conventionallytreated) group.”
BackgroundMitochondrial DNA: A New Predictor of Diabetic Kidney Disease
Huang, Y., Chi, J., Wei, F., Zhou, Y., Cao, Y., & Wang, Y. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3650937 · Cited by 28
Maanaoui, M., Lenain, R., Foucher, Y., Buron, F., Blancho, G., Antoine, C., Caillard, S., Kessler, L., Le Quintrec, M., Villard, O., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00241-9 · Cited by 23
Bjornstad, P., Pyle, L. L., Kinney, G. L., Rewers, M., Johnson, R. J., Maahs, D. M., & Snell‐Bergeon, J. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.012 · Cited by 22
Ferrannini, G., Norhammar, A., Gyberg, V., Mellbin, L., & Rydén, L. (2020) · Diabetes Care · doi:10.2337/dci20-0002 · Cited by 28
Metadata
- Authors
- de Boer, I. H., & for the DCCT/EDIC Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 24-30
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3867994
- OpenAlex
- W2160388935
- Semantic Scholar
- 0e25853fef3a739d11a78c1cdc288086bfda2756
- Cited by
- 254
- References
- 38
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 20 · 2023: 26 · 2022: 28 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 16 · 2017: 12 · 2016: 16 · 2015: 27 · 2014: 11 · 2013: 3
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, RC4DK090766, R01DK088762, P30DK017047)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, diabetic nephropathy, urinary albumin excretion rate, microalbuminuria, macroalbuminuria, glomerular filtration rate, intensive diabetes therapy, glycemic control, hypertension, DCCT/EDIC
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypertension, Insulin, Kidney, Male, Middle Aged, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.